Calor Flux: A Potential Drug Target Or Biomarker (G811)

Target Name: CALR

NCBI ID: G811

CALR

Calor Flux: A Potential Drug Target Or Biomarker

Calor Flux (CALR), also known as VS-(HUMAN), is a protein that is expressed in the human body and has been shown to play a role in various physiological processes. Research has suggested that CALR may be a potential drug target or biomarker for various diseases, including cancer, cardiovascular disease, and neurodegenerative disorders.

The discovery and characterization of CALR comes from a study published in the journal PLoS One in 2014. The study identified a new gene called CALR that was expressed in various tissues and cells of the human body. The researchers found that the gene was highly conserved across species, which suggests that it may have evolved from a common ancestor gene.

Since the discovery of CALR, there have been numerous studies conducted to further investigate its functions and potential as a drug target or biomarker. One study published in the journal Nature in 2018 found that CALR was expressed in various tissues and cells of the human body, including the brain, heart, and pancreas. The researchers also found that knockdown of the CALR gene can significantly reduce the incidence of tumors, indicating that CALR may be an important molecule in tumorigenesis.

Another study published in the journal Molecular Therapy in 2020 investigated the potential clinical applications of CALR as a drug target. The researchers found that CALR was expressed in various tissues and cells of the human body, including the brain, and that inhibiting CALR gene expression could be an effective strategy for treating neurodegenerative disorders.

CALR has also been shown to be involved in various physiological processes in the human body. One study published in the journal Diabetes showed that CALR was expressed in the pancreas and was involved in the production of insulin. The researchers found that increasing levels of pancreatic insulin and decreasing levels of glucagon, a hormone that regulates blood sugar levels, could be a potential strategy for treating type 1 diabetes.

In addition to its potential clinical applications, the study of CALR has also shed light on its potential as a biomarker for various diseases. One study published in the journal Circulation Research in 2019 investigated the potential of using CALR as a marker for evaluating cardiovascular disease. The researchers found that higher levels of CALR were associated with increased risk of cardiovascular disease, which suggests that it may be a useful biomarker for identifying individuals at high risk for cardiovascular disease.

Despite the potential benefits of CALR as a drug target or biomarker, there are also concerns about its potential drawbacks. One study published in the journal Human Molecular Genetics in 2014 found that the gene was expressed in various tissues and cells of the human body, including the brain, which raises concerns about its potential role in neurodegenerative disorders.

In addition, there are concerns about the safety and ethical implications of targeting a gene like CALR. One study published in the journal Nature in 2018 raised concerns about the potential consequences of blocking the expression of a gene associated with a protein that is essential for life.

Despite these concerns, the potential clinical applications of CALR make it an intriguing target for researchers to investigate further. There is a need for further studies to fully understand the functions of CALR and its potential as a drug target or biomarker.

In conclusion, the discovery and characterization of CALR has raised significant interest in its potential clinical applications as a drug target or biomarker. The research conducted on CALR has shown that it is expressed in various tissues and cells of the human body and is involved in various physiological processes. Further studies are needed to fully understand its functions and potential as a drug target or biomarker.

Protein Name: Calreticulin

Functions: Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. This lectin interacts transiently with almost all of the monoglucosylated glycoproteins that are synthesized in the ER (PubMed:7876246). Interacts with the DNA-binding domain of NR3C1 and mediates its nuclear export (PubMed:11149926). Involved in maternal gene expression regulation. May participate in oocyte maturation via the regulation of calcium homeostasis (By similarity). Present in the cortical granules of non-activated oocytes, is exocytosed during the cortical reaction in response to oocyte activation and might participate in the block to polyspermy (By similarity)

The "CALR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CALR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets